Overview
The National Cancer Institute (NCI), Division of Cancer Treatment and Diagnosis (DCTD), will host a two-day virtual workshop focused on accelerating the translation of emerging cancer diagnostics and enabling technologies into measurable clinical impact. The meeting will convene experts and stakeholders from across DCTD programs, including the Cancer Diagnosis Program (CDP), Cancer Imaging Program (CIP), Radiation Research Program (RRP), and the Small Business Innovation Research (SBIR) program together with senior investigators, early-stage investigators, and industry leaders in a solution-oriented forum designed to bridge scientific innovation to real-world clinical implementation.
Workshop objective:
To accelerate translation from discovery to clinical adoption by (i) showcasing next-generation biomarker and enabling technology platforms, (ii) strengthening cross-sector collaboration across academia, industry, and government, (iii) engaging and supporting both senior investigators and early-stage investigators through focused discussion, visibility, and mentorship, and (iv) outlining NCI-supported funding, partnership, and commercialization pathways that advance measurable clinical impact.
Day 1 spotlights foundational innovation in biomarker science; Day 2 is focused on industry perspectives, funding pathways, and awardee case studies to align projects with available NCI funding mechanisms.
Register now to participate!